Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus

Fantini, Massimo Claudio

;Fiorino, Gionata;Colli, Agostino;Laharie, David;Armuzzi, Alessandro;Caprioli, Flavio Andrea;Gisbert, Javier P;Kirchgesner, Julien;Macaluso, Fabio Salvatore;Magro, Fernando;Ghosh, Subrata;PRACTICE-IBD study group;Onali, Sara

Member of the Collaboration Group

2024-01-01

---

Abstract

Background and Aims Pragmatic studies designed to test interventions in everyday clinical settings can successfully complement the evidence from registration and explanatory clinical trials. The European consensus project PRACTICE-IBD was developed to identify essential criteria and address key methodological issues needed to design valid, comparative, pragmatic studies in inflammatory bowel diseases [BDs].Methods Statements were issued by a panel of 11 European experts in IBD management and trial methodology, on four main topics: [I] study design; [II] eligibility, recruitment and organisation, flexibility; [III] outcomes; [IV] analysis. The consensus process followed a modified Delphi approach, involving two rounds of assessment and rating of the level of agreement [1 to 9; cut-off >= 7 for approval] with the statements by 18 additional European experts in IBD.Results At the first voting round, 25 out of the 26 statements reached a mean score >= 7. Following the discussion that preceded the second round of voting, it was decided to eliminate two statements and to split one into two. At the second voting round, 25 final statements were approved: seven for study design; six for eligibility, recruitment and organisation, flexibility; eight for outcomes; and four for analysis.Conclusions Pragmatic, randomised, clinical trials can address important questions in IBD clinical practice, and may provide complementary, high-level evidence, as long as they follow a methodologically rigorous approach. These 25 statements intend to offer practical guidance in the design of high-quality, pragmatic, clinical trials that can aid decision making in choosing a management strategy for IBDs.